Monoclonal Antibodies

Loncastuximab Tesirine for Non-Hodgkin's Lymphoma

Fred Hutch/University of Washington Cancer Consortium, Seattle, WA
Targeting 11 different conditionsLoncastuximab TesirinePhase 2RecruitingLed by Stephen D. SmithResearch Sponsored by University of Washington

Study Summary

This trial tests whether a targeted therapy drug shrinks tumors in patients with B-cell malignancies that have come back or does not respond to treatment.

Eligible Conditions
  • Non-Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Lymphoproliferative Disorder
  • B-Cell Lymphoma
  • Non-Hodgkin's Lymphoma

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have a specific disease that needs to meet certain criteria for inclusion in the study.
You have a type of non-Hodgkin lymphoma called B-NHL that has come back or is not responding to treatment. Tests have shown that you have very low or no expression of the CD19 protein. You have already tried at least one treatment before, and your doctor doesn't think there is a better treatment option for you.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall response rate (ORR)
Secondary outcome measures
Clinical benefit rate
Duration or response
Incidence of grade 3-5 drug-related toxicity
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (loncastuximab tesirine)Experimental Treatment1 Intervention
Patients receive loncastuximab tesirine IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Find a site

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,684 Previous Clinical Trials
1,687,058 Total Patients Enrolled
Stephen D. SmithPrincipal Investigator
Fred Hutch/University of Washington Cancer Consortium
2 Previous Clinical Trials
53 Total Patients Enrolled

Media Library

Loncastuximab Tesirine (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05453396 — Phase 2
Non-Hodgkin's Lymphoma Research Study Groups: Treatment (loncastuximab tesirine)
Non-Hodgkin's Lymphoma Clinical Trial 2023: Loncastuximab Tesirine Highlights & Side Effects. Trial Name: NCT05453396 — Phase 2
Loncastuximab Tesirine (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05453396 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Loncastuximab Tesirine obtained regulatory clearance from the FDA?

"There is some evidence of Loncastuximab Tesirine's safety, so it earned a score of 2. The lack of efficacy data precludes the medication from receiving higher mark."

Answered by AI

Is this research currently open to participants?

"This investigation is not currently recruiting study participants, as it was last updated on November 2nd 2022. However, there are 3609 other medical trials actively searching for patients to enroll in their studies."

Answered by AI
~27 spots leftby Dec 2025